Biocon expands its strategic partnership with CytoSorbents

04 Nov 2014 Evaluate

Biocon, Asia’s premier biopharmaceuticals company, and US-based CytoSorbents Corporation, have expanded the scope of their strategic partnership for CytoSorbents’ CytoSorb cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS). SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.

Biocon will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the intensive care unit (ICU) as well as cardiac surgery applications for India and select emerging countries. As part of the expanded agreement, Biocon will also play a prominent leadership role in the generation of new clinical evidence to support the adoption and usage of CytoSorb. This includes commitments to conduct and publish results from multiple Investigator Initiated Trials (IITs) and patient case studies.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

370.10 -2.55 (-0.68%)
23-Jan-2026 12:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1643.90
Dr. Reddys Lab 1247.40
Cipla 1382.95
Zydus Lifesciences 890.50
Lupin 2158.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×